Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth...
12 KB (867 words) - 22:03, 29 May 2025
price), helping to boost its complement of cancer drugs, specifically repotrectinib. That same month, the company announced it would be investing $180m...
97 KB (7,698 words) - 04:30, 26 May 2025
(INN) Repan reparixin (USAN) Repatha repifermin (INN) repirinast (INN) repotrectinib (INN) repromicin (INN) Repronex reproterol (INN) Requip Resa Resaid...
6 KB (350 words) - 19:22, 10 April 2025
Odronextamab Pazopanib Pexidartinib Pralsetinib Quizartinib Regorafenib Repotrectinib Ripretinib Selpercatinib Sitravatinib Sorafenib Sunitinib Surufatinib...
12 KB (829 words) - 20:43, 29 May 2025
Odronextamab Pazopanib Pexidartinib Pralsetinib Quizartinib Regorafenib Repotrectinib Ripretinib Selpercatinib Sitravatinib Sorafenib Sunitinib Surufatinib...
12 KB (731 words) - 21:34, 29 May 2025
for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC) Repotrectinib (TPX-0005, Turning Point Therapeutics) Belizatinib (TSR-011, Tesaro)...
17 KB (1,959 words) - 19:53, 29 May 2025
L01EX25 Umbralisib L01EX26 Sitravatinib L01EX27 Capivasertib L01EX28 Repotrectinib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab...
13 KB (932 words) - 04:36, 23 December 2024
deletions or exon 21 L858R mutations, as detected by an FDA-approved test Repotrectinib Treatment of people aged twelve years of age and older with solid tumors...
45 KB (248 words) - 21:21, 29 May 2025